Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Neurology 1999;52:1427
© 1999 American Academy of Neurology
Articles

A controlled trial of recombinant methionyl human BDNF in ALS

The BDNF Study Group (Phase III)*

Address correspondence and reprint requests to Dr. Walter G. Bradley, Department of Neurology (D4-5), University of Miami School of Medicine, P.O. Box 016960, Miami, FL 33101.

OBJECTIVE: To replicate the beneficial effect of brain-derived neurotrophic factor (BDNF) in 1,135 ALS patients in a multicenter trial.

BACKGROUND: In a phase I through II study, BDNF appeared to increase survival and retard loss of pulmonary function in ALS patients.

METHODS: Patients were randomized to placebo, or 25 or 100 µg/kg BDNF for 9 months.

RESULTS: The study failed to show benefit of BDNF treatment for the primary end points. Survival in patients treated with 25 µg/kg BDNF was identical to placebo, but there was a trend toward increased survival in the 100-µg/kg group. As a whole, survival was better than anticipated when planning the study. The 9-month probability of survival was approximately 85% across all groups. This diminished the power of the study. Among the 60% of patients with baseline forced vital capacity of <=91%, survival was significantly greater for 100 µg/kg BDNF versus placebo. For the 20% of patients treated with 100 µg/kg BDNF reporting altered bowel function as an adverse effect of BDNF in the first 2 weeks of dosing, defined as BDNF "responders," 9-month survival was significantly better than for placebo (97.5% versus 85%).

CONCLUSIONS: Although the primary end point analysis failed to demonstrate a statistically significant survival effect of BDNF in ALS, post hoc analyses showed that those ALS patients with early respiratory impairment and those developing altered bowel function showed statistically significant benefit. Further clinical trials of BDNF using either intrathecal delivery or high-dose subcutaneous administration are in progress.




This article has been cited by other articles:


Home page
 NeurologyHome page
C. L. Howe, R. A. Bergstrom, B. F. Horazdovsky, E.J. Sorenson, A.J. Windbank, J.N. Mandrekar, W.R. Bamlet, S.H. Appel, C. Armon, P.E. Barkhaus, et al.
SUBCUTANEOUS IGF-1 IS NOT BENEFICIAL IN 2-YEAR ALS TRIAL
Neurology, October 13, 2009; 73(15): 1247 - 1248.
[Full Text] [PDF]

Home page
 J Child NeurolHome page
J. Montes, A. M. Gordon, S. Pandya, D. C. De Vivo, and P. Kaufmann
Clinical Outcome Measures in Spinal Muscular Atrophy
J Child Neurol, August 1, 2009; 24(8): 968 - 978.
[Abstract] [PDF]

Home page
 NeurologyHome page
P. H. Gordon, B. Cheng, I. B. Katz, H. Mitsumoto, and L. P. Rowland
Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS
Neurology, June 2, 2009; 72(22): 1948 - 1952.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. M. Fletcher, C. J. Morton, R. A. Zwar, S. S. Murray, P. D. O'Leary, and R. A. Hughes
Design of a Conformationally Defined and Proteolytically Stable Circular Mimetic of Brain-derived Neurotrophic Factor
J. Biol. Chem., November 28, 2008; 283(48): 33375 - 33383.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
W Boesmans, P Gomes, J Janssens, J Tack, and P V. Berghe
Brain-derived neurotrophic factor amplifies neurotransmitter responses and promotes synaptic communication in the enteric nervous system
Gut, March 1, 2008; 57(3): 314 - 322.
[Abstract] [Full Text] [PDF]

Home page
 Sci SignalHome page
W. Dauer
Neurotrophic Factors and Parkinson's Disease: The Emergence of a New Player?
Sci. Signal., November 6, 2007; 2007(411): pe60 - pe60.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
R. Miller, W. Bradley, M. Cudkowicz, J. Hubble, V. Meininger, H. Mitsumoto, D. Moore, H. Pohlmann, D. Sauer, V. Silani, et al.
Phase II/III randomized trial of TCH346 in patients with ALS
Neurology, August 21, 2007; 69(8): 776 - 784.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. Lo Coco, S. Marchese, V. La Bella, T. Piccoli, and A. Lo Coco
The Amyotrophic Lateral Sclerosis Functional Rating Scale Predicts Survival Time in Amyotrophic Lateral Sclerosis Patients on Invasive Mechanical Ventilation
Chest, July 1, 2007; 132(1): 64 - 69.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
H. Mitsumoto, A. M. Ulug, S. L. Pullman, C. L. Gooch, S. Chan, M. -X. Tang, X. Mao, A. P. Hays, A. G. Floyd, V. Battista, et al.
Quantitative objective markers for upper and lower motor neuron dysfunction in ALS
Neurology, April 24, 2007; 68(17): 1402 - 1410.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
Y. K. Cheung, P. H. Gordon, and B. Levin
Selecting promising ALS therapies in clinical trials
Neurology, November 28, 2006; 67(10): 1748 - 1751.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
R. B. Choudry and M. E. Cudkowicz
Clinical Trials in Amyotrophic Lateral Sclerosis: The Tenuous Past and the Promising Future
J. Clin. Pharmacol., December 1, 2005; 45(12): 1334 - 1344.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P. Kaufmann, G. Levy, J. L.P. Thompson, M. L. DelBene, V. Battista, P. H. Gordon, L. P. Rowland, B. Levin, and H. Mitsumoto
The ALSFRSr predicts survival time in an ALS clinic population
Neurology, January 11, 2005; 64(1): 38 - 43.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
K. Maeda, A. Sawada, M. Matsubara, Y. Nakai, A. Hara, and T. Yamamoto
A Novel Neuroprotectant against Retinal Ganglion Cell Damage in a Glaucoma Model and an Optic Nerve Crush Model in the Rat
Invest. Ophthalmol. Vis. Sci., March 1, 2004; 45(3): 851 - 856.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. D. O'Leary and R. A. Hughes
Design of Potent Peptide Mimetics of Brain-derived Neurotrophic Factor
J. Biol. Chem., July 3, 2003; 278(28): 25738 - 25744.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X.-H. Liu, R. J. Collier, and R. J. Youle
Inhibition of Axotomy-induced Neuronal Apoptosis by Extracellular Delivery of a Bcl-XL Fusion Protein
J. Biol. Chem., November 30, 2001; 276(49): 46326 - 46332.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
I. A. Scarisbrick, P. J. Isackson, and A. J. Windebank
Differential Expression of Brain-Derived Neurotrophic Factor, Neurotrophin-3, and Neurotrophin-4/5 in the Adult Rat Spinal Cord: Regulation by the Glutamate Receptor Agonist Kainic Acid
J. Neurosci., September 15, 1999; 19(18): 7757 - 7769.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. P. Ringel
Practicing neurology: A delicate balance
Neurology, May 1, 1999; 52(8): 1526 - 1526.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by AAN Enterprises, Inc.